

06-29-00

A

Please type a plus sign (+) inside this box ☒

UTILITY PATENT APPLICATION TRANSMITTAL

Attorney Docket No.

CDS-222

First Named Inventor or Application Identifier

Robert De Leys and Jian Zheng

Express Mail Label No.

EM208320125US

(only for new nonprovisional applications under 37 CFR 1.53(b))

APPLICATION ELEMENTS

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

See MPEP Chapter 600 concerning utility patent application contents.

1. ☒ Fee Transmittal Form (attached hereto in duplicate)
2. ☒ Specification [Total Pages 59]
(Preferred arrangement set forth below)
 - Descriptive Title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R&D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
3. ☒ Drawing(s) (35 USC 113) [Total Sheets 10]
4. Declaration and Power of Attorney
 - a. ☐ Newly executed (original or copy)
 - b. ☐ Unexecuted original
 - c. ☒ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional check boxes 5 and 16)
 - i. ☐ Deletion of Inventor(s)
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
5. ☒ Incorporation by Reference
(useable if Box 4c is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4c, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

6. ☐ Microfiche Computer Program (Appendix)
7. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
 - a. ☒ Computer Readable Copy
 - b. ☒ Paper Copy (identical to computer copy)
 - c. ☒ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. ☒ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(b) Statement
(when there is an assignee) ☐ Power of Attorney
10. ☐ English Translation Document (if applicable)
11. ☐ Information Disclosure Statement
(IDS)/PTO-1449 ☐ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
14. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)

15. ☐ Other:

16. ☒ If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:
Amend the specification by inserting before the first line: -- This is a ☐ Continuation ☒ Divisional
☐ Continuation-in-Part (CIP) of prior application No.: 09/433,428, filed November 4, 1999. --
17. For this divisional application, please cancel original Claims 3 and 5 of the prior application before calculating the filing fee.

18. CORRESPONDENCE ADDRESS

☐ Customer Number or Bar Code Label or ☒ Correspondence Address below

Name: Audley A. Ciamporcerro, Jr., Esq.
Address: Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003 USA


19. TELEPHONE CONTACT

Please direct all telephone calls or telefaxes to Stacey B. Antar at:
Telephone: (732) 524-2824 Fax: (732) 524-2808

19. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

NAME Stacey B. Antar Reg. No. 39595

SIGNATURE



DATE

June 28, 2000

06/28/00

06/28/00 U.S. PTO

06/28/00 U.S. PTO

09/605573

06/28/00

PEPTIDES FOR THE DETECTION OF HIV-1 GROUP O

Background

5 The principal etiological agent responsible for causing what has come to be known as acquired immunodeficiency syndrome (AIDS) is a non-transforming retrovirus belonging to the lentivirus genus (1). This virus, referred to as Human Immunodeficiency Virus type I (HIV-1), is now widely disseminated and constitutes a serious threat to health and productivity worldwide. Virtually all
10 industrialized countries, as well as many in the developing world, now mandate the testing of blood donations to prevent the further transmission of this virus and the spread of disease through the use of contaminated blood and blood products. A related, genetically distinct, but less wide-spread and pathologically less aggressive virus capable of inducing similar disease was
15 reported in 1986, and is referred to as HIV-2 (2). While HIV-2 is found primarily in West Africa and is less widely disseminated than HIV-1, many countries require the screening of blood donations for antibodies to this virus as well. An HIV-1 is disclosed in EP-178 978, while an HIV-2 is disclosed in EP-0 239 425.

20 One feature which is characteristic of human immunodeficiency viruses is their sequence variability. The genomes of all HIVs encode the enzyme reverse transcriptase. This enzyme, which the virus requires to convert its RNA genome into its double-stranded DNA equivalent prior to integration into host cell DNA, is essential for virus replication. Unlike many polymerases, this
25 Mg⁺²-dependent enzyme lacks a 3'→5' exonuclease activity which normally serves a proofreading function. As a consequence, this enzyme tends to be error-prone. Within any HIV-infected individual, many naturally occurring sequence variants of the virus can be found, not all of which are viable. This observation has given rise to the notion of the quasi-species, a term used to

describe a particular strain of HIV infecting an individual as a collection of all its closely related, naturally occurring sequence variants (3).

In addition to naturally occurring sequence variants within an infected individual, phylogenetic analyses of HIV-1 strains collected from all over the world have demonstrated that these strains can be grouped into at least 9 types (A - I) based on the similarity of their sequences (4). The differences between the types are greater than the differences observed between individual virus variants within a single infected person, or the differences between other variants belonging to the same type. The geographical distribution of these HIV-1 types varies significantly, with certain types being prevalent in one particular geographic region but rare or absent in another. Collectively, these HIV-1 types may be considered to form a group, which is usually referred to as group M (major).

In 1987, a highly divergent variant of HIV-1 was isolated that was immunologically easily distinguishable from commonly encountered HIV strains (5). This variant is described in EP-0 345 375, US Patents 5,304,466, and US 5,567,603. This virus (ANT70) was antigenically closer to HIV-1 reference strains than it was to HIV-2, but was nevertheless clearly very different. The sequence of the entire provirus was subsequently determined (6). While the genome organization of this virus confirmed that this isolate was an HIV-1, a comparison of its sequence with those of many other reference strains showed that this virus was highly divergent, and phylogenetic analyses placed this isolate in its own unique branch of the HIV phylogenetic tree.

In 1991, a second, highly divergent HIV-1 strain (MVP5180) was isolated and described (7). This isolate was disclosed in EP-0 591 914, and was found to cluster phylogenetically with ANT70. The genetic distance between these two isolates was approximately as great as the distance between the virus types belonging to group M. Together, these two isolates defined a new group of

HIV-1 isolates. Because these isolates clustered outside the normal cluster of conventional HIV-1 isolates, they represented a new group, usually referred to as group O (outlier).

5 In 1992, a third person was identified in France who was infected with a group O strain (8). The sequence of the immunologically important viral *env* gene was determined, and is described in WO 96/12809. Subsequently, several additional group O-infected patients were identified in France (9), and the sequence of portions of the viral *env* proteins of these isolates was also determined. These sequences have been described in PCT/FR96/00294. An
10 analysis of all of the available sequences showed that they cluster together in the branch of the HIV-1 phylogenetic tree corresponding to group O. Unlike group M, there seems to be little evidence for the existence of discrete virus types within the outlier group. With the exception of the French VAU isolate, virtually all of the group O isolates to date share a link to West-Central Africa. In this portion of Africa, it has been estimated that between 5% and 8% of all
15 cases of HIV-1 infection are caused by group O variants, however, these percentages are strongly dependent on the specific geographical region (10, 11).

20 While there seems to be no significant differences between group M and group O strains in terms of pathology or disease progression, the detection of antibodies produced in response to a group O infection can be unreliable when the antigens used for serological testing are derived exclusively from group M strains (12, 13). Although antibodies produced to group O antigens will often cross-react with the corresponding group M antigens, the sensitivity for
25 anti-group O antibodies can be significantly improved by incorporating a group O antigen into the test.

Although the existence of HIV-1 groups and types is well-established, an increasing number of isolates have been identified that cannot be conveniently

assigned to a specific HIV-1 group M type. Through sequence analysis it has been possible to demonstrate that these isolates are the products of recombination between viruses belonging to two or more different types. In some cases, multiple recombination events must have occurred, giving rise to "mosaic" genomes. Multiple types have been shown to coexist within a single patient, and there have been reports of multiple group M types coexisting in a patient together with a group O strain (14, 15). Since the genomes of group M and group O strains also share regions which are very highly conserved, legitimate recombination could presumably occur between these viruses as well.

A preferred antigen for the detection of antibodies produced in response to HIV infection is the transmembrane portion of the viral envelope protein. This protein, referred to as gp41, is cleaved from a gp160 precursor in the infected cell by a cellular protease. This protein contains the viral fusion peptide at its N-terminus, which the virus needs in order to fuse with and penetrate a new host cell. It also provides an anchor for the surface envelope glycoprotein gp120, which is responsible for recognizing CD4 molecules and co-receptors for the virus on the surface of susceptible cells. The interaction between gp120 and gp41 is, however, non-covalent and somewhat labile. The gp41 protein is itself anchored in the viral or host cell membrane via a hydrophobic membrane-spanning region.

Little is known of the detailed three-dimensional structure of this protein. A limited amount of structural information concerning the extracellular domain of this protein is available from the Brookhaven Protein Data Base. However, the immunologically most relevant portion of gp41 is absent, probably because it is too mobile to give rise to reflections. A comparison of viral gp41 amino acid sequences corresponding to this immunologically important region reveals the presence of several extremely highly conserved amino acids in what is

presumably the top of a tight disulfide-stabilized loop, suggesting that these amino acids serve an essential structural and functional role.

Summary of the Invention

5

This invention relates to peptides, their preparation and use. Each peptide has a sequence that corresponds to the immunodominant region of the HIV-1 group O gp41 envelope protein. The sequence is characterized in that it does not correspond to any known naturally occurring group O variant.

10

In another aspect, this invention relates to a peptide, as described above, that is antigenic. Preferentially it binds anti-HIV-1 group O antibodies.

15

In yet another aspect, this invention relates to the use of the peptide, as described above, for the detection of antibodies produced in response to HIV-1 group O infection.

20

In yet another aspect, this invention relates to compositions and kits for determining the presence of HIV-1 group O antibodies, comprising the peptide as described above or its analog.

25

In yet another aspect, this invention relates to anti-HIV-1 group O antibodies and their production using the peptides, and their use in detecting HIV-1 antigens and HIV-1 infection.

A preferred peptide referred to herein as "peptide 147" comprising the following amino acid sequence:

(SEQ ID NO:59)

NQQRLNSWGCKGRIICYTSARWH,

30

wherein the amino-terminus is at the left of the sequence. The peptide may be modified chemically (16) at either end to endow it with properties that will facilitate its use, such as N-terminal acetylation, biotinylation, or the addition of a spacer arm to provide physical distance between the peptide and a functional group used to anchor the peptide to a solid phase or a carrier.

In addition to peptide 147 several variations of the amino acid sequence of peptide 147 were found to be useful.

A preferred peptide related 147 comprises the following amino acid sequence:

(SEQ ID NO:60) XQQRLNSWGCKGRIICYTSARWH,

wherein X can be any natural amino acid other than L-asparagine or a non-natural amino acid, that is, one that is not among the 20 recognized naturally occurring amino acids; but which may occur naturally or be of human design.

Another peptide related to 147 comprises the following amino acid sequence:

(SEQ ID NO:62) ETLMQXQQRLNSWGCKGRIICYTSARWH,

wherein X denotes any natural amino acid other than L-asparagine, or a non-natural amino acid.

Each of the preferred peptides may be modified chemically at their the amino or carboxyl terminus to endow it with properties that will facilitate its use such as, but not limited to, N-terminal acetylation, biotinylation, or the addition of a spacer group to provide physical distance between the peptide and a functional group used to anchor the peptide to a solid phase or a carrier.

The invention further relates to the preparation of a mosaic. A mosaic is a recombinant group M gp41 protein in which the group M immunodominant region has been replaced by an O-like immunodominant sequence. An α -helical antigenic region located downstream from the immunodominant region was also modified in a way to increase its likelihood of being recognized by anti-group O antibodies, while still retaining those amino acids required for inter-helix interactions and structural stabilization of the protein. The resulting recombinant is therefore an artificially constructed group M/group O hybrid that does not exist in nature.

In another aspect, this invention relates to the use of a recombinant protein, as described above, for the detection of antibodies produced in response to HIV-1 group O infection.

In another aspect, this invention relates to a recombinant protein, as described above, that preferentially binds anti-HIV-1 group O antibodies.

In yet another aspect, this invention relates to compositions and kits for determining the presence of HIV-1 group O antibodies, comprising a recombinant protein as described above.

In yet another aspect, this invention relates to anti-HIV-1 group O antibodies and their production using the recombinant protein, and their use in detecting HIV-1 antigens and HIV-1 infection.

Preferred group O replacements are:

i) (SEQ ID NO:64) RARLQALETLMQNQQRLNSWGCKGRIICYTSARWH,
and

ii) (SEQ ID NO:65) DQQVNNVSSIIYDKILEAQDQQEENVRELLELD

wherein the amino-terminus is at the left of the sequence.

The recombinant protein may be modified chemically at either end to endow it with properties that will facilitate its use, such as N-terminal acetylation, biotinylation, or the addition of a spacer arm to provide physical distance between the protein and a functional group used to anchor it to a solid phase or a carrier.

In yet another aspect, this invention relates to compositions and kits comprising a peptide or recombinant protein, as described above, and one or more antigens directed to other anti-HIV-1 type antibodies.

In yet another aspect, this invention relates to methods for detecting HIV-1 infection using a peptide or recombinant protein, as described above, in combination with one or more antigens directed to other HIV-1 type antibodies.

Brief Description of the Drawings

- Figure 1. Alignment of HIV-1 group O immunodominant region amino acid sequences (SEQ ID NO:1-30).
- Figure 2. Recognition of peptides 147 and 80 by an HIV-1 group O sample.
- Figure 3. Ectodomain of gp41 (MN isolate) (SEQ ID NO:70)
- Figure 4. Alignment of MN (type B) and group O gp41 sequences in the region of the descending helix (SEQ ID NO:31-45)
- Figures 5 a-c. The stepwise reconstruction and replacement of the immunodominant region using overlapping synthetic oligonucleotides.

Figure 5 d. The nucleotide sequence of the primers used in Figures a-c (SEQ ID NO:46-56).

Figure 6 a The amino acid sequence of DHFR-hENV-MH (SEQ ID NO:57).

5 Figure 6 b. The amino acid sequence of DHFR-hES-MH (SEQ ID NO:58).

Detailed Description of the Invention

10 A "sample" as used herein, refers to any substance which may contain the analyte of interest. A sample can be biological fluid, such as whole blood or whole blood components including red blood cells, white blood cells, platelets, serum and plasma, ascites, urine, cerebrospinal fluid, and other constituents of the body which may contain the analyte of interest

15 An "antibody" as used herein may be may be monoclonal or polyclonal and may be of any species of origin, including for example, human, rat, mouse, rabbit, horse, sheep, or may be chimeric antibodies. The antibodies may be recombinant monoclonal antibodies or chemically constructed. See M. Walker et al. Molec. Immunol. 26, 403-11 (1989); U.S. Patent 4,474,893; U.S. Patent 4,816,567; and U.S. Patent 4,676,980.

20 An "antigen" as used herein refers to any substance that as a result of coming in contact with appropriate tissues of an animal body, induces a state of sensitivity and/or resistance to infection. "Antigenic" means immunogenic or having the properties of an antigen, including but not limited to the generation of antibodies that bind the antigen. Antigens can be proteins, oligopeptides, or polypeptides and can be prepared using recombinant technology as well as synthetic methods.

25
30 For the purposes of the present invention it should be noted that because the genetic code is degenerate, more than one codon may be used to

encode a particular amino acid, and therefore, the amino acid sequence can be encoded by any of a set of similar DNA oligonucleotides.

Furthermore, it is known that there is a substantial amount of redundancy in the various codons which code for specific amino acids. Therefore, this invention is also directed to those DNA sequences which contain alternative codons which code for the eventual translation of the identical amino acid. For purposes of this specification, a sequence bearing one or more replaced codons will be defined as a degenerate variation. Also included within the scope of this invention are mutations either in the DNA sequence or the translated protein which do not substantially alter the ultimate physical properties of the expressed protein. For example, substitution of valine for leucine, arginine for lysine, or asparagine for glutamine may not cause a change in functionality of the peptide.

As used herein, a "functional derivative" of the peptide is a compound that possesses a biological activity (either functional or structural) that is substantially similar to the biological activity of the peptide of the invention. The term "functional derivatives" is intended to include the "fragments," "variants," "degenerate variants," "analogs" and "homologues" or to "chemical derivatives" of the peptide. The term "fragment" is meant to refer to any subset of the peptide. The term "variant" is meant to refer to a molecule substantially similar in structure and function to either the entire mosaic or peptide molecule or to a fragment thereof. A molecule is "substantially similar" to the mosaic or peptide if both molecules have substantially similar structures or if both molecules possess similar biological activity. Therefore, if the two molecules possess substantially similar activity, they are considered to be variants even if the structure of one of the molecules is not found in the other or even if the two amino acid sequences are not identical. The

term "analog" refers to a molecule substantially similar in function to either the entire mosaic or peptide molecule or to a fragment thereof.

Following expression of the peptide in a recombinant host cell several peptide purification procedures are available and suitable for use. For example, the peptide may be purified from cell lysates and extracts, or from conditioned culture medium, by various combinations of, or individual application of salt fractionation, ion exchange chromatography, size exclusion chromatography, hydroxylapatite adsorption chromatography and hydrophobic interaction chromatography . In addition, recombinant peptides can be separated from other cellular proteins by use of an immunoaffinity column made with monoclonal or polyclonal antibodies specific for full length peptides, or fragments.

Examples are set forth below. The example are intended to illustrate and not limit the invention.

Example 1

Sequences. To determine which amino acids were characteristic of group O strains, gp41 sequences from as many different isolates possible (complete and partial) were collected and aligned. Many of these sequences were available from the scientific literature, while others were determined in this laboratory. Attention was focused towards the region of gp41 known to be immunodominant and of particular diagnostic value. The sequences used for the comparison were obtained from the following sources:

Sequence	reference
ANT70	6
MVP5180	7
VAU	8
DUR	WO 96/12809
POC, FAN, LOB, MAN, NAN, ESS, NKO, BCF09, BCF12, BCF13, BCF14	PCT/FR96/00294
686	17
ABT063, ABT124, ABT1123, ABT2156, 193Ha	18
CDC7755, CDC1897	19
HLD28, 1515, 1516, D47-2d, HCYT2c, Nr42, PE41	this laboratory

Table 1. Sources of HIV-1 group O sequences

Viral amino acid sequences were trimmed to a 33 amino acid-fragment containing the immunodominant region of gp41 and were aligned using the program MEGALIGN (DNASar). The alignment is shown in Figure 1.

The height of the column above each amino acid position shows graphically how well the amino acid in each position is conserved. Of the 33 positions in the region of interest, 18 amino acids are perfectly conserved in all strains. In the other 15 positions that are less well conserved, a closer examination of the amino acids found in these positions reveals that there is frequently a preference for amino acids with certain characteristics. For example, in positions 9 and 25, there is a strong preference for an amino acid with a hydrophobic side chain. There is also a strong preference for a lysine residue in position 21, and a positively charged amino acid in position 23.

Because it is known that the immunodominant region is primarily situated between amino acids 11 and 33 in the region shown in Table 3, a peptide sequence was derived in which an amino acid is incorporated in each position that can also be found in a naturally occurring strain. However, the resulting sequence is unique and does not correspond to that of any known group O

virus. This sequence is approximately 62% identical to that of the original ANT70 isolate.

The amino acid sequence of the peptide (peptide 147) is as follows:

5

(SEQ ID NO:59) NQQLNSWGCKGRIICYTSARWH

The following sequence alignment shows the similarities and differences between this sequence and the sequence of the original ANT70 isolate:

10

(SEQ ID NO:68) ANT70 NQQLSLWGCKGKLV CYTSVKWN

(SEQ ID NO:59) peptide 147 NQQLNSWGCKGRIICYTSARWH

15

Peptide synthesis. Peptide synthesis was carried out using 9-fluorenylmethoxycarbonyl (Fmoc) chemistry on commercially available polystyrene:divinylbenzene-crosslinked resin bearing the modified Rink linker in order to generate peptides with a C-terminal amide following cleavage. Protected amino acids were activated *in situ* using an equimolar quantity of N-[(dimethylamino)-1*H*-1,2,3-triazolo[4,5-*b*]pyridin-1-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide (HATU) and 1-hydroxy-7-azabenzotriazole (HOAt), and a 2-fold molar excess of N-methylmorpholine (NMM) in N-methylpyrrolidone (NMP). A 4-fold excess of activated amino acid was used with respect to the loading capacity of the resin. Trityl (Trt) side-chain protection was used for glutamine, asparagine, cysteine, and histidine. The hydroxyl functions of serine, threonine, and tyrosine were protected with the *t*-butyl (*t*Bu) group, the side chain of lysine was protected with the *t*-butyloxycarbonyl (*t*Boc) group, and 2,2,5,7,8-pentamethylchroman-6-sulfonyl (Pmc) group was used for the side chain of arginine. All other amino acids were coupled without side chain protection.

30

Removal of the Fmoc group at the beginning of each cycle was achieved by treating the resin-bound peptide with a mixture of 2% 1,8-diazabicyclo[5.4.0]undec-7-ene and 2% piperidine in NMP for 15 minutes.

5

To facilitate the binding of the peptide to the solid phase for testing, the peptide was synthesized with a biotin residue at its amino terminus. Two glycine residues were added to the N-terminus of the peptide to serve as a spacer arm before attaching the biotin. Biotin was coupled by *in situ* activation of its carboxyl group using an equimolar quantity of O-(benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU) and a 2-fold molar excess of NMM. The biotin was dissolved in 30% dimethylsulfoxide (DMSO), 70% NMP prior to activation.

10

15

Cleavage of the resin-bound peptide was accomplished by treating the peptide resin using a mixture of trifluoroacetic acid, phenol, thioanisole, ethanedithiol, and water (82.5:5:5:2.5:5) (reagent K). Following cleavage, the peptide-containing cleavage mixture was filtered off and the volume reduced in a rotary evaporator. Methyl-*t*-butylether was then added to precipitate the peptide. The precipitated crude peptide was collected by filtration, dried under vacuum, and purified by reversed phase HPLC. Fractions containing the desired product were identified by electrospray mass spectrometry, lyophilized, and stored desiccated at 4°C.

20

25

Example 2

Serological recognition of the peptide by HIV-1 group O sera.

Peptide 147 was evaluated for its ability to be recognized by anti-HIV-1 group O antibodies present in human serum from infected individuals. All group O samples were confirmed to be positive for HIV-1 group O by reverse transcriptase-polymerase chain reaction (RT-PCR) amplification of viral gp41

30

sequences using O-specific primers. The identity of the PCR product was further confirmed by DNA sequencing.

A preferred method for demonstrating antibody binding is the enzyme-linked immunosorbent assay (ELISA). This technique involves binding of the antigen to a solid phase, bringing the fluid to be tested into contact with the antigen-coated solid phase, washing away any unbound material, and then detecting bound antibodies with an enzyme-labeled second antibody. The presence of the enzyme is detected using a chromogenic or luminogenic substrate.

To evaluate biotinylated peptide 147, wells of a microtiter plate were coated with streptavidin at a concentration of 1 $\mu\text{g/ml}$ in 50 mM carbonate buffer, pH 9.6 (200 $\mu\text{l/well}$). Excess unbound streptavidin was removed by washing several times with phosphate buffered saline (PBS). Biotinylated peptide 147 was dissolved in a minimal volume of pure DMSO and then diluted into PBS to a concentration of 0.5 $\mu\text{g/ml}$. Two hundred microliters of the peptide solution were added to each well and the peptide allowed to bind to the streptavidin. After removing unbound peptide by washing with PBS, serum samples obtained from HIV-1 group O-infected patients were added to the wells of the plate. After a suitable incubation period, unbound material was removed by washing with PBS. A dilution of an anti-IgG:horse radish peroxidase (HRP) conjugate was added to each well and incubated for 30 minutes at 37°C. Unbound material was removed by extensive washing. Substrate solution containing O-phenylenediamine (OPD) and H_2O_2 was added to each well and the plate was further incubated, protected from light. After a 30 minute incubation period at room temperature, the reaction was terminated by the addition of 50 μl of 4N H_2SO_4 and the absorbance of each well was read at 492 nm.

Peptide 147 was first tested by using undiluted (10 μ l) serum samples. The results are shown in Table 2. The sample measurements are in optical density (OD).

undiluted samples	OD492
negative control	0.056
ODS001	2.500
ODS002	2.500
ODS003	2.500
ODS004	2.500
ODS006	2.500
ODS007a	2.500
ODS007b	2.500
ODS009	2.500
type B sample	1.926

Table 2. Recognition of peptide 147 using undiluted specimens.

Samples ODS007a and b are consecutive bleeds from the same individual. The negative control sample is from an uninfected blood donor. These results show that antibodies produced in response to an HIV-1 group O infection are capable of recognizing peptide 147.

A panel of serially diluted group O sera was tested with peptide 147 in order to evaluate the sensitivity of an ELISA using this antigen. Streptavidin-coated plates were prepared and loaded with peptide 147 as before, and tested using the dilutional panels. In addition, in order to compare the performance of peptide 147 with that of a genuine group O sequence, a second peptide was synthesized (peptide 146) corresponding to the sequence of the DUR variant. These peptides cover precisely the same region of gp41, and were tested in parallel. These results are shown in Table 3:

Panel	Sample	dilution of original sample	OD ₄₉₂	
			peptide 147	peptide 146
OP1	OP1A	2	2.500	1.732
	OP1B	4	2.298	0.563
	OP1C	8	2.465	1.481
	OP1D	16	2.387	1.186
	OP1E	32	2.013	0.978
	OP1F	64	1.448	0.356
	OP1G	128	1.150	0.432
	OP1H	256	0.927	0.258
	OP1I	512	0.504	0.123
	OP1J	1024	0.053	0.015
OP2	OP2A	5	2.236	1.831
	OP2B	10	2.320	1.822
	OP2C	20	2.157	1.142
	OP2D	40	1.844	0.775
	OP2E	80	1.061	0.613
	OP2F	160	0.689	0.104
	OP2G	320	0.327	0.076
	OP2H	640	0.184	0.060
	OP2I	1280	0.179	0.041
	OP2J	2560	0.090	0.045
OP3	OP3A	300	0.229	0.334
	OP3B	600	0.373	0.334
	OP3C	1200	0.211	0.132
OP4	OP4A	100	0.774	1.220
	OP4B	200	0.608	0.726
	OP4C	400	0.398	0.608
	OP4D	800	0.277	0.430
	OP4E	1600	0.040	0.051
OP5	OP5A	100	1.624	1.100
	OP5B	200	1.027	0.74
	OP5C	400	0.225	0.205
	OP5D	800	0.302	0.264
OP6	OP6A	50	0.667	1.905
OP7-2	OP7-2A	100	2.081	2.302
	OP7-2B	200	1.817	2.104
	OP7-2C	400	1.346	1.568
	OP7-2D	800	0.847	0.935

Table 3. Sensitivity of antibody detection using peptide 147.

These results demonstrate that even with highly diluted samples, peptide 147 is a suitable antigen capable of binding antibodies against the group O gp41 immunodominant region. With a number of the panels, the performance of peptide 147 equaled or significantly exceeded that of a genuine group O sequence.

To compare the performance of peptide 147 to another genuine group O sequence, the peptide corresponding to the ANT70 sequence was synthesized (peptide 80). Peptides 147 and 80 were dissolved at the same concentration, serially diluted, and bound to streptavidin-coated wells. A 1:60 dilution of serum sample ODS007b (see Table 3) was added to all wells and incubated. After washing, an anti-human IgG:HRP conjugate was added, incubated, and the wells again thoroughly washed. In this case, a chemiluminescent substrate was used, consisting of luminol and a peracid salt. The emitted light was quantified using a luminometer. The results are tabulated in Table 4 and shown graphically in Figure 2.

peptide (ug/ml)	luminescent units	
	peptide 147	peptide 80
2.500	2.374	1.821
1.250	2.885	2.908
0.625	3.093	2.854
0.313	2.090	2.294
0.156	1.199	1.288
0.078	0.740	0.621
0.039	0.504	0.376
0.020	0.619	0.387

Table 4. Comparison of antibody recognition of peptides 147 and 80.

These results demonstrate that the amino acid sequence of peptide 147 is comparable to that of a naturally occurring isolate for the detection of antibodies to HIV-1 group O.

5 Example 3

Antibody recognition of variants of peptide 147:

The following two peptides were synthesized:

10 Peptide 147-4:
(SEQ ID NO:61) EQQRLNSWGCKGRIICYTSARWH

Peptide 147-5:
(SEQ ID NO:69) GRETLMQDQQRLNSWGCKGRIICYTSARWH

15 In peptide 147-5, the N-terminal glycine was added to function as a spacer group, while the arginine in position 2 was added to enhance the solubility of the peptide in aqueous buffers. Both of these peptides were evaluated for their ability to be recognized by HIV-1 group O serum samples in an antibody capture format. In general, in such an assay, a peptide is bound to a solid phase and bivalent antibody presents in a sample binds to the peptide linked thereto. Bound antibody is subsequently detected using a conjugate made of the peptide in question coupled to horseradish peroxidase. The peptide-HRP conjugate binds to antibody which in turn is bound to the solid phase linked peptide. Methods suitable for preparing such conjugates may be found readily in the scientific literature and are well known to those versed in the art.

20

25

Microwell plates were pre-coated with either peptide 147-4 or 147-5. A dilution of a serum sample was then incubated for 1 hour at 37°C, after which the plate was washed extensively. A 1:100 dilution of either peptide 147-4 or 147-5

30

conjugated to HRP was then added and allowed to incubate for an additional hour at 37°C. Following this incubation, the plates were again thoroughly washed. The presence of bound conjugate was detected by addition of substrate for HRP (O-phenylenediamine) and H₂O₂. Antibody recognition of peptides 147-4 and 147-5 is shown in Table 5 below.

sample (dilution)	Optical Density (OD) ₄₉₂	
	peptide 147-4 Ag peptide 147-4 conjugate	peptide 147-5 Ag peptide 147-5 conjugate
negative control	0.010	0.022
ODS001 (1:200)	>2.500	>2.500
ODS002 (1:175)	0.785	1.343
ODS006 (1:100)	0.133	0.266
ODS007 (1:1,500)	0.241	0.316

Table 5. Antibody recognition of peptides 147-4 and 147-5

The peptides were evaluated for their ability to be recognized by anti-HIV-1 group O antibodies present in human serum from infected individuals. All group O samples were confirmed to be positive for HIV-1 group O by reverse transcriptase-polymerase chain reaction (RT-PCR) amplification of viral gp41 sequences using O-specific primers. The identity of the PCR product was further confirmed by DNA sequencing.

The results presented in the table demonstrate that the noted sequence variations of peptide 147 are suitable for detecting the presence of antibodies produced in response to an HIV-1 group O infection, even when the serum samples are highly diluted. The results also indicate that the use of the longer peptide results in a somewhat higher signal than the shorter version.

It is possible to introduced variations to the basic amino acid sequence of peptide 147 and retain the ability to detect antibodies produced in response to infection by HIV-1 group O.

5

Example 4

Design of a recombinant antigen for antibody detection. In many cases, larger proteins often function better than short peptides for the detection of antibodies because they are able to present discontinuous epitopes created by the juxtaposition of distant regions of the polypeptide chain in the native protein. Other advantages to using recombinant proteins include the ability to incorporate into the protein specific sequences unrelated to the actual antigen in order to facilitate purification of the protein, binding to the solid phase, or to provide the protein with other desirable characteristics.

10

15

The sequence of the group M HIV-1 type B isolate MN was used as a point of departure in designing a novel antigen with desirable characteristics for the detection of anti-group O antibodies. The *env* gene product is a polypeptide 855 amino acids in length. Cleavage of the gp160 precursor occurs between amino acids 513 and 514 to give rise to the envelope proteins gp120 and gp41 found in mature virions. Of particular interest for antibody detection is the ectodomain of gp41, shown in Figure 3.

20

25

The design of a new recombinant protein should take into account any available structural information to avoid creating a protein that is intrinsically hindered in its ability to re-form its native structure in solution. The structures 1AIK and 1ENV were obtained from the Brookhaven Protein Database and viewed using the programs Rasmol and SwissModel. These crystallographic structures show the presence of two interacting helices which form a coiled coil. The sequences connecting these two helices in the 1ENV structure (and

30

which encompass the immunodominant region) are absent, suggesting that the interconnecting region comprising the immunogenic region at the top of a loop is too mobile to generate reflections. The helices for which there is crystallographic data are indicated in Figure 3. The N- and C-terminal limits to each helix are the limits for which crystallographic data is available; they are not necessarily the true boundaries of these helices in the native gp41 protein.

The potential importance of sequences contained within the "descending" helix shown in Figure 3 has been demonstrated for group O sera and are described in WO 95/32293. To determine which amino acids in the MN sequence should not be mutated, the available 3-dimensional structures were examined to identify those amino acids likely to be involved in stabilizing the interactions between the two helices. The following close contacts were identified:

G548 → N657

Q551 → Q653

Q552 → Q654

A562 → I643

H565 → Y639

L569 → I636

W572 → W632

W572 → W629

An examination of available sequences in the HIV Sequence Data Base maintained by the Los Alamos National Laboratory reveals that many of these amino acids are highly conserved. Mutations, when present, often have similar characteristics, such as a hydrophobic side-chain or a side-chain with the ability to participate in hydrogen bonding. The sequence of the MN isolate in the region of the descending helix (amino acids 633 - 665) was aligned and

compared to that of all group O strains for which sequence information is available. This alignment is shown in Figure 4.

Figure 4 also shows which amino acids in this region are conserved, even between the type B sequence and the group O sequences. This sequence comparison suggests very strongly that there is a high degree of structural homology between group M and group O strains.

To arrive at a sequence representative of group O, only the group O sequences were considered. The sequence chosen after evaluation of the amino acids found in each position is as follows:

(SEQ ID NO:65) DQQVNNVSSIIYDKILEAQDQQEENVRELLELD

This sequence has 57.6% identity to the corresponding ANT70 sequence.

Additionally, the peptide 147 group O-like immunodominant region was extended in the N-terminal direction. This larger immunodominant region has the following sequence:

(SEQ ID NO:64) RARLQALETLMQNQQRLNSWGCKGRIICYTSARWH

With the N-terminal extension, this new sequence has 68.6% identity with the original ANT70 strain.

It would be understood by one skilled in the art that a diagnostic test could be developed using either the peptides or derivatives thereof as described herein to detect antibodies found in an infected patient, or using antibodies raised against the aforementioned peptides to detect antigen found in an infected patient.

Example 5

Construction of a "mosaic" group M/group O recombinant antigen.

Having taken structural features of gp41 into account and knowing that the
5 sequence contained within peptide 147 is suitable for the detection of
anti-group O antibodies, the construction of a mosaic recombinant was
undertaken. The objective was to use the MN gp41 sequence as a point of
departure and substitute the two group O regions described above, thereby
10 creating a group O antigen using the type B MN sequence as a carrier for the
immunologically important domains.

The strategy for constructing such a recombinant is shown in Figures 5a - c.
The stepwise reconstruction and replacement of the immunodominant region
15 using overlapping synthetic oligonucleotides is illustrated, along with all
important restriction enzyme cleavage sites.

The sequences of the primers used are given in Figure 5d.

Two constructs were made as dihydrofolate reductase (DHFR) fusion proteins.
20 Neither of the constructs represents a full-length gp41 molecule, however, the
longer of the two (DHFR-hENV-MH) contains essentially the entire ectodomain
of gp41 except for the N-terminal fusion peptide. The construct
DHFR-hES-MH is a truncated version of the longer fusion protein. The amino
acid sequences of these fusion proteins are shown in Figure 6, a. and b.

25 A C-terminal sequence derived from the *myc* gene was added to facilitate
analysis, and a his_6 tail was added to facilitate purification. All non-HIV
sequences are shown in boxes. The group O-like sequences are underlined.
All other sequences in the HIV portion of this recombinant are group
30 group M-derived.

The expression of both proteins was attempted in *Escherichia coli*. The greatest level of expression was observed for the truncated construct DHFR-hES-MH and the expressed recombinant protein was found in inclusion bodies. The cells were lysed, and the inclusion bodies harvested by well known methods. The protein was subsequently solubilized by treatment with sodium dodecyl sulfate (SDS) and dithiothreitol, and analyzed by polyacrylamide gel electrophoresis in the presence of SDS. A band was observed having the expected molecular size and was estimated to constitute about 90% of the total protein in the crude antigen preparation.

Example 6

Performance of group M/group O "mosaic" constructs for group O antibody detection. The protein expressed as described was coated at a concentration of 0.5 µg/ml into the wells of microtiter plates for evaluation. Following coating of the protein, any remaining binding sites on the plastic were block with bovine serum albumin. Dilutions of group O sera were then tested for their ability to recognize the recombinant antigen. Bound antibodies were detected by incubation with HRP-labeled mouse anti-human IgG conjugate, and the bound conjugate was subsequently detected by addition of OPD and H₂O₂. The results are shown in Table 6.

Table 6:

Sample	OD492	
	wild type	DHFR-hES-MH
neg. control 1	0.186	-0.061
ODS001	0.056	1.179
ODS002	1.209	1.323
type B sample	1.579	0.685

Because these antigens were derived by taking into consideration a reasonably large number of HIV-1 group O sequences, the new sequences are thought to better represent the spectrum of group O variants which are likely to occur in nature and may therefore have a broader specificity for the detection of anti-group O antibodies. Experimental results show that these antigens function as well, and in some cases better, than naturally occurring viral sequences for the detection of antibodies generated in response to HIV-1 group O infections.

The use of "mosaic" recombinants offer advantages in that they display the desired antigenic determinants but can be more easily bound by direct coating to a solid phase than peptides for use in an immunoassay. Furthermore, the recombinants, because of their increased length and more stabilized structure relative to peptides, present the determinants more accurately.

All cited materials herein are hereby incorporated by reference. Accordingly, it should be noted that the present invention includes all modifications falling within the scope of the following claims.

Literature cited

1. Barré-Sinoussi, F., et al., **Science** (1983) 220:868-871.
2. Clavel, F., et al., **Science** (1986) 233:343-346.
3. Goodenow, M., et al., **J. Acquir. Immun. Defic. Syndr.** (1989) 2:344-352.
4. Leitner, T., et al., **Human Retroviruses and AIDS Compendium 1997** (1998), part III, pp. 19-24.
5. DeLeys, R., et al., **J. Virol.** (1990) 64:1207-1216.
6. Vanden Haesevelde, M., et al., **J. Virol.** (1994) 68:1586-1596.
7. Gürtler, L.G., et al., **J. Virol.** (1994) 68:1581-1585.
8. Charneau, P., et al., **Virology** (1994) 205:247-253.

9. Loussert-Ajaka, I., et al., **J. Virol.** (1995) 69:5640-5649.
10. Maucière, P., et al., **AIDS** (1997) 11:445-453.
11. Peeters, M., et al., **AIDS** (1997) 11:493-498.
12. Loussert-Ajaka, I., et al., **Lancet** (1994) 343:1393-1394.
- 5 13. Britvan, L., et al., **MMWR** (1996) 45:561-565.
14. Heyndrickx, L., et al., **Lancet** (1996) 347:902-903.
15. Takehisa, J., et al., **J. Acquir. Immun. Defic. Syndr.** (1997) 14:81-82.
16. Hermanson, G.T.; **Bioconjugate Techniques**, Academic Press, San Diego, U.S.A., 1996.
- 10 17. Delaporte, E., et al., **AIDS** (1996) 10:903-910.
18. Brennan, C., et al., **AIDS Res. Human. Retrovir.** (1997) 13:901-904.
19. Hackett, J., et al., **Fourth Conf. on Retroviruses and Opportun. Infect., Washington, D.C.** (1997), abstr. 160.

SEQUENCE LISTING

<110> De Leys, Robert J.
Zheng, Jian

5

<120> PEPTIDES FOR THE DETECTION OF HIV-1 GROUP O

<130> CDS-207

10

<140> Not Assigned

<141> 1999-11-04

<160> 69

15

<170> PatentIn Ver. 2.0

<210> 1

<211> 33

<212> PRT

20

<213> Human immunodeficiency virus type 1

<400> 1

Arg Leu Leu Ala Leu Glu Thr Leu Leu Gln Asn Gln Gln Leu Leu Ser
1 5 10 15

25

Leu Trp Gly Cys Lys Gly Lys Leu Val Cys Tyr Thr Ser Val Lys Trp
20 25 30

Asn

30

<210> 2

<211> 33

<212> PRT

35

<213> Human immunodeficiency virus type 1

<400> 2

Arg Leu Gln Ala Leu Glu Thr Leu Ile Gln Asn Gln Gln Arg Leu Asn
1 5 10 15

40

Leu Trp Gly Cys Lys Gly Lys Leu Ile Cys Tyr Thr Ser Val Lys Trp
20 25 30

45

Asn

<210> 3
 <211> 33
 <212> PRT
 <213> Human immunodeficiency virus type 1

5

<400> 3
 Arg Leu Leu Ala Leu Glu Thr Phe Ile Gln Asn Gln Gln Leu Leu Asn
 1 5 10 15

10

Leu Trp Gly Cys Lys Asn Arg Leu Ile Cys Tyr Thr Ser Val Lys Trp
 20 25 30

Asn

15

<210> 4
 <211> 33
 <212> PRT
 <213> Human immunodeficiency virus type 1

20

<400> 4
 Arg Leu Leu Ala Leu Glu Thr Leu Ile Gln Asn Gln Gln Leu Leu Asn
 1 5 10 15

25

Leu Trp Gly Cys Lys Gly Arg Leu Val Cys Tyr Thr Ser Val Lys Trp
 20 25 30

Asn

30

<210> 5
 <211> 33
 <212> PRT
 <213> Human immunodeficiency virus type 1

35

<400> 5
 Arg Leu Leu Ala Leu Glu Thr Leu Ile Gln Asn Gln Gln Leu Leu Asn
 1 5 10 15

40

Leu Trp Gly Cys Lys Gly Arg Leu Ile Cys Tyr Thr Ser Val Lys Trp
 20 25 30

45

Asn

<210> 6
 <211> 33
 <212> PRT
 <213> Human immunodeficiency virus type 1

5

<400> 6
 Arg Leu Leu Ala Leu Glu Thr Leu Ile Gln Asn Gln Gln Leu Leu Asn
 1 5 10 15

10

Ser Trp Gly Cys Lys Gly Arg Leu Val Cys Tyr Thr Ser Val Glu Trp
 20 25 30

Asn

15

<210> 7
 <211> 33
 <212> PRT
 <213> Human immunodeficiency virus type 1

20

<400> 7
 Arg Leu Leu Ala Leu Glu Thr Leu Ile Gln Asn Gln Gln Leu Leu Asn
 1 5 10 15

25

Ser Trp Gly Cys Lys Gly Arg Gln Val Cys Tyr Thr Ser Val Lys Trp
 20 25 30

Asn

30

<210> 8
 <211> 33
 <212> PRT
 <213> Human immunodeficiency virus type 1

35

<400> 8
 Arg Leu Leu Ala Leu Glu Thr Leu Ile Gln Asn Gln Gln Leu Leu Asn
 1 5 10 15

40

Leu Trp Gly Cys Lys Gly Arg Leu Ile Cys Tyr Thr Ser Val Gln Trp
 20 25 30

45

Asn

<210> 9
 <211> 33
 <212> PRT
 <213> Human immunodeficiency virus type 1

5

<400> 9
 Arg Leu Leu Ala Leu Glu Thr Leu Met Gln Asn Gln Gln Leu Leu Asn
 1 5 10 15

10

Leu Trp Gly Cys Lys Gly Arg Ile Leu Cys Tyr Thr Ser Val Lys Trp
 20 25 30

Asn

15

<210> 10
 <211> 33
 <212> PRT
 <213> Human immunodeficiency virus type 1

20

<400> 10
 Arg Leu Leu Ala Leu Glu Thr Leu Ile Gln Asn Gln Gln Leu Leu Asn
 1 5 10 15

25

Leu Trp Gly Cys Lys Gly Arg Ile Val Cys Tyr Thr Ser Val Arg Trp
 20 25 30

Asn

30

<210> 11
 <211> 33
 <212> PRT
 <213> Human immunodeficiency virus type 1

35

<400> 11
 Arg Leu Leu Ala Leu Glu Thr Leu Ile Gln Asn Gln Gln Leu Leu Asn
 1 5 10 15

40

Leu Trp Gly Cys Lys Gly Lys Ile Val Cys Tyr Thr Ser Val Glu Trp
 20 25 30

45

Asn

<210> 12
 <211> 33
 <212> PRT
 <213> Human immunodeficiency virus type 1

5

<400> 12
 Arg Leu Leu Ala Leu Glu Thr Leu Met Gln Asn Gln Gln Leu Leu Asn
 1 5 10 15

10

Leu Trp Gly Cys Lys Gly Lys Leu Ile Cys Tyr Thr Ser Val Arg Trp
 20 25 30

Asn

15

<210> 13
 <211> 33
 <212> PRT
 <213> Human immunodeficiency virus type 1

20

<400> 13
 Arg Leu Gln Ala Leu Glu Thr Leu Ile Gln Asn Gln Gln Arg Leu Asp
 1 5 10 15

25

Leu Trp Gly Cys Lys Gly Arg Ile Ile Cys Tyr Thr Ser Val Lys Trp
 20 25 30

Asn

30

<210> 14
 <211> 33
 <212> PRT
 <213> Human immunodeficiency virus type 1

35

<400> 14
 Arg Leu Leu Ala Leu Glu Thr Phe Ile Gln Asn Gln Gln Leu Leu Asn
 1 5 10 15

40

Leu Trp Gly Cys Lys Gly Arg Leu Ile Cys Tyr Thr Ser Val Lys Trp
 20 25 30

45

Asn

<210> 15
 <211> 33
 <212> PRT
 <213> Human immunodeficiency virus type 1

5

<400> 15
 Arg Leu Leu Ala Leu Glu Thr Leu Ile Gln Asn Gln Gln Leu Leu Asn
 1 5 10 15

10

Leu Trp Gly Cys Lys Gly Arg Leu Val Cys Tyr Thr Ser Val Lys Trp
 20 25 30

Asn

15

<210> 16
 <211> 33
 <212> PRT
 <213> Human immunodeficiency virus type 1

20

<400> 16
 Arg Leu Leu Ala Leu Glu Thr Leu Ile Gln Asn Gln Gln Leu Leu Asn
 1 5 10 15

25

Ser Trp Gly Cys Gln Gly Lys Leu Val Cys Tyr Thr Ser Val Ile Trp
 20 25 30

Asn

30

<210> 17
 <211> 33
 <212> PRT
 <213> Human immunodeficiency virus type 1

35

<400> 17
 Arg Leu Gln Ala Leu Glu Thr Leu Met Gln Asn Gln Gln Leu Leu Asn
 1 5 10 15

40

Leu Trp Gly Cys Lys Gly Lys Ser Ile Cys Tyr Thr Ser Val Lys Trp
 20 25 30

45

Asn

<210> 18
<211> 33
<212> PRT
<213> Human immunodeficiency virus type 1

5

<400> 18
Arg Leu Leu Ala Leu Glu Thr Phe Val Gln Asn Gln Gln Leu Leu Asn
1 5 10 15

10

Leu Trp Gly Cys Lys Gly Arg Ile Val Cys Tyr Thr Ser Val Lys Trp
20 25 30

Asn

15

<210> 19
<211> 33
<212> PRT
<213> Human immunodeficiency virus type 1

20

<400> 19
Arg Leu Leu Ala Leu Glu Thr Leu Met Gln Asn Gln Gln Leu Leu Asn
1 5 10 15

25

Leu Trp Gly Cys Arg Gly Lys Ala Ile Cys Tyr Thr Ser Val Gln Trp
20 25 30

Asn

30

<210> 20
<211> 33
<212> PRT
<213> Human immunodeficiency virus type 1

35

<400> 20
Arg Leu Gln Ala Leu Glu Thr Leu Ile Gln Asn Gln Gln Leu Leu Ser
1 5 10 15

40

Leu Trp Gly Cys Lys Gly Arg Leu Val Cys Tyr Thr Ser Val Lys Trp
20 25 30

45

His

<210> 21
 <211> 33
 <212> PRT
 <213> Human immunodeficiency virus type 1

5

<400> 21
 Arg Leu Leu Ala Leu Glu Thr Leu Ile Gln Asn Gln Gln Leu Leu Asn
 1 5 10 15

10

Leu Trp Gly Cys Lys Gly Arg Leu Leu Cys Tyr Thr Ser Val Lys Trp
 20 25 30

Asn

15

<210> 22
 <211> 33
 <212> PRT
 <213> Human immunodeficiency virus type 1

20

<400> 22
 Arg Leu Leu Ala Leu Glu Thr Phe Ile Gln Asn Gln Gln Leu Leu Asn
 1 5 10 15

25

Leu Trp Gly Cys Lys Gly Lys Leu Ile Cys Tyr Thr Ser Val Glu Trp
 20 25 30

Asn

30

<210> 23
 <211> 33
 <212> PRT
 <213> Human immunodeficiency virus type 1

35

<400> 23
 Arg Leu Gln Ala Leu Glu Thr Leu Met Gln Asn Gln Gln Arg Leu Asp
 1 5 10 15

40

Leu Trp Gly Cys Lys Gly Arg Leu Ile Cys Tyr Thr Ser Val Lys Trp
 20 25 30

45

Asn

<210> 24
 <211> 33
 <212> PRT
 <213> Human immunodeficiency virus type 1

5

<400> 24
 Arg Leu Gln Ala Leu Glu Pro Leu Ile Gln Asn Gln Gln Arg Leu Ser
 1 5 10 15

10

Leu Trp Gly Cys Lys Gly Arg Ile Ile Cys Tyr Thr Ser Ala Lys Trp
 20 25 30

Asn

15

<210> 25
 <211> 33
 <212> PRT
 <213> Human immunodeficiency virus type 1

20

<400> 25
 Arg Leu Leu Ala Leu Glu Thr Leu Ile Gln Asn Gln Gln Leu Leu Asn
 1 5 10 15

25

Ser Trp Gly Cys Lys Gly Arg Leu Val Cys Tyr Thr Ser Val Lys Trp
 20 25 30

Asn

30

<210> 26
 <211> 33
 <212> PRT
 <213> Human immunodeficiency virus type 1

35

<400> 26
 Arg Leu Val Ala Leu Glu Thr Leu Val Gln Asn Gln Gln Leu Leu Asn
 1 5 10 15

40

Leu Trp Gly Cys Lys Gly Arg Leu Thr Cys Tyr Thr Ser Val Lys Trp
 20 25 30

45

Asn

<210> 27
<211> 33
<212> PRT
<213> Human immunodeficiency virus type 1

5

<400> 27
Arg Leu Leu Ala Leu Glu Thr Leu Ile Gln Asn Gln Gln Leu Leu Asn
1 5 10 15

10

Leu Trp Gly Cys Lys Gly Arg Leu Leu Cys Tyr Thr Ser Val Lys Trp
20 25 30

Asn

15

<210> 28
<211> 33
<212> PRT
<213> Human immunodeficiency virus type 1

20

<400> 28
Arg Leu Leu Ala Leu Glu Thr Phe Ile Gln Asn Gln Gln Leu Leu Asn
1 5 10 15

25

Leu Trp Gly Cys Lys Gly Gln Leu Val Cys Tyr Thr Ser Val Lys Trp
20 25 30

Asn

30

<210> 29
<211> 33
<212> PRT
<213> Human immunodeficiency virus type 1

35

<400> 29
Arg Leu Leu Ala Leu Glu Thr Phe Ile Gln Asn Gln Gln Leu Leu Asn
1 5 10 15

40

Leu Trp Gly Cys Lys Gly Arg Leu Ile Cys Tyr Thr Ser Val Lys Trp
20 25 30

45

Asn

<210> 30
 <211> 33
 <212> PRT
 <213> Human immunodeficiency virus type 1

5

<400> 30
 Arg Leu Leu Ala Leu Glu Thr Leu Ile Gln Asn Gln Gln Leu Leu Asn
 1 5 10 15

10

Ser Trp Gly Cys Lys Gly Arg Ile Val Cys Tyr Thr Ser Val Lys Trp
 20 25 30

Asn

15

<210> 31
 <211> 33
 <212> PRT
 <213> Human immunodeficiency virus type 1

20

<400> 31
 Glu Arg Glu Ile Asp Asn Tyr Thr Ser Leu Ile Tyr Ser Leu Leu Glu
 1 5 10 15

25

Lys Ser Gln Thr Gln Gln Glu Lys Asn Glu Gln Glu Leu Leu Glu Leu
 20 25 30

Asp

30

<210> 32
 <211> 33
 <212> PRT
 <213> Human immunodeficiency virus type 1

35

<400> 32
 Asp Arg Gln Ile Ser Asn Ile Ser Ser Thr Ile Tyr Glu Glu Ile Gln
 1 5 10 15

40

Lys Ala Gln Val Gln Gln Glu Gln Asn Glu Lys Lys Leu Leu Glu Leu
 20 25 30

45

Asp

<210> 33
 <211> 33
 <212> PRT
 <213> Human immunodeficiency virus type 1

5

<400> 33
 Asp Gln His Ile Asn Asn Val Ser Ser Ile Ile Tyr Asp Glu Ile Gln
 1 5 10 15

10

Ala Ala Gln Asp Gln Gln Glu Lys Asn Val Lys Ala Leu Leu Glu Leu
 20 25 30

Asp

15

<210> 34
 <211> 33
 <212> PRT
 <213> Human immunodeficiency virus type 1

20

<400> 34
 Asp Gln Gln Ile Asn Asn Val Ser Ser Phe Ile Tyr Glu Lys Ile Gln
 1 5 10 15

25

Glu Ala Gln Glu Gln Gln Glu Lys Asn Glu Lys Glu Leu Leu Glu Leu
 20 25 30

Asp

30

<210> 35
 <211> 33
 <212> PRT
 <213> Human immunodeficiency virus type 1

35

<400> 35
 Asp Gln Gln Ile Asp Asn Ile Ser Ser Thr Ile Tyr Asp Glu Ile Gln
 1 5 10 15

40

Lys Ala Gln Val Gln Gln Glu Gln Asn Glu Gln Lys Leu Leu Glu Leu
 20 25 30

45

Asp

<210> 36
 <211> 33
 <212> PRT
 <213> Human immunodeficiency virus type 1

5

<400> 36
 Asp Gln Gln Ile Asn Asn Ile Ser Ser Ile Ile Tyr Gly Glu Ile Gln
 1 5 10 15

10

Lys Ala Gln Val Gln Gln Glu Glu Asn Glu Lys Lys Leu Leu Glu Leu
 20 25 30

Asp

15

<210> 37
 <211> 33
 <212> PRT
 <213> Human immunodeficiency virus type 1

20

<400> 37
 Asp Gln Gln Ile Asn Asn Ile Ser Ser Ile Ile Tyr Gly Glu Ile Gln
 1 5 10 15

25

Lys Ala Gln Val Gln Gln Glu His Asn Glu Lys Lys Leu Leu Glu Leu
 20 25 30

Asp

30

<210> 38
 <211> 33
 <212> PRT
 <213> Human immunodeficiency virus type 1

35

<400> 38
 Asp Gln Gln Val Asn Asn Val Ser Ser Phe Ile Tyr Asp Lys Ile Gln
 1 5 10 15

40

Glu Ala Gln Glu Gln Gln Glu Glu Asn Glu Arg Ala Leu Leu Glu Leu
 20 25 30

45

Asp

<210> 39
 <211> 33
 <212> PRT
 <213> Human immunodeficiency virus type 1

5

<400> 39
 Asp Gln Gln Ile Ser Asn Val Ser Ser Ile Ile Tyr Glu Glu Ile Gln
 1 5 10 15

10

Lys Ala Gln Glu Gln Gln Glu Gln Asn Glu Lys Lys Leu Leu Glu Leu
 20 25 30

Asp

15

<210> 40
 <211> 33
 <212> PRT
 <213> Human immunodeficiency virus type 1

20

<400> 40
 Asp Gln Gln Ile Ala Asn Val Ser Ser Phe Ile Tyr Asp Gln Ile Gln
 1 5 10 15

25

Glu Ala Gln Glu Arg Gln Asp Lys Asn Glu Lys Thr Leu Leu Glu Leu
 20 25 30

Asp

30

<210> 41
 <211> 33
 <212> PRT
 <213> Human immunodeficiency virus type 1

35

<400> 41
 Asp Gln Gln Ile Asp Asn Val Ser Ser Thr Ile Tyr Glu Glu Ile Leu
 1 5 10 15

40

Lys Ala Gln Ile Gln Gln Glu Gln Asn Glu Lys Lys Leu Leu Glu Leu
 20 25 30

45

Asp

<210> 42
<211> 33
<212> PRT
<213> Human immunodeficiency virus type 1

5

<400> 42
Asp Arg Glu Ile Asp Asn Ile Ser Ser Tyr Ile Tyr Glu Lys Ile Gln
1 5 10 15

10

Glu Ala Gln Asp Gln Gln Glu Asn Asn Glu Arg Glu Leu Leu Glu Leu
20 25 30

Asp

15

<210> 43
<211> 33
<212> PRT
<213> Human immunodeficiency virus type 1

20

<400> 43
Asp Lys Gln Ile Ser Asn Ile Ser Ser Ile Ile Tyr Asp Glu Ile Gln
1 5 10 15

25

Thr Ala Gln Asp Gln Gln Glu Arg Asn Val Lys Ala Leu Leu Glu Leu
20 25 30

Asp

30

<210> 44
<211> 33
<212> PRT
<213> Human immunodeficiency virus type 1

35

<400> 44
Asp Gln Gln Val Asn Asn Val Ser Ser Ile Ile Tyr Glu Glu Ile Gln
1 5 10 15

40

Arg Ala Gln Val Gln Gln Glu Gln Asn Glu Lys Arg Leu Leu Glu Leu
20 25 30

45

Asp

<210> 45
 <211> 33
 <212> PRT
 <213> Human immunodeficiency virus type 1

5

<400> 45
 Asp Gln Gln Ile Asp Asn Val Ser Ser Ile Ile Tyr Glu Glu Ile Gln
 1 5 10 15

10

Lys Ala Gln Gly Gln Gln Glu Gln Asn Glu Lys Lys Leu Leu Glu Leu
 20 25 30

Asp

15

<210> 46
 <211> 63
 <212> DNA
 <213> Artificial Sequence

20

<220>
 <223> Description of Artificial Sequence: HIV Consensus
 Sequence

25

<400> 46
 attttggaag cccaggatca acaagaggag aacgttcgtg agttgctgga gctagataaa 60
 tgg 63

30

<210> 47
 <211> 58
 <212> DNA
 <213> Artificial Sequence

35

<220>
 <223> Description of Artificial Sequence: HIV Consensus
 Sequence

40

<400> 47
 agcaagttaa caatgtttct tctattatct atgataagat tttggaagcc caggatca 58

45

<210> 48
 <211> 63
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: HIV Consensus
 Sequence

50

<400> 48
 attttggaag cccaggatca acaagaggag aacgttcgtg agttgctgga gctagataaa 60
 tgg 63

5
 <210> 49
 <211> 58
 <212> DNA
 <213> Artificial Sequence

10
 <220>
 <223> Description of Artificial Sequence: HIV Consensus Sequence

15
 <400> 49
 agcaagttaa caatgtttct tctattattt atgataagat tttggaagcc caggatca 58

20
 <210> 50
 <211> 62
 <212> DNA
 <213> Artificial Sequence

25
 <220>
 <223> Description of Artificial Sequence: HIV Consensus Sequence

30
 <400> 50
 ccagatatcc tccagagact tattagacca agaagcatgc caacgggcac tagtataaca 60
 aa 62

35
 <210> 51
 <211> 62
 <212> DNA
 <213> Artificial Sequence

40
 <220>
 <223> Description of Artificial Sequence: HIV Consensus Sequence

45
 <400> 51
 acattgttaa cttgctggtc ccattgcac caggatcatgt tatcccagat atcctccaga 60
 ga 62

50
 <210> 52
 <211> 62
 <212> DNA
 <213> Artificial Sequence

55
 <220>
 <223> Description of Artificial Sequence: HIV Consensus Sequence

60
 <400> 52
 ccagatatcc tccagagact tattagacca agaagcatgc caacgggcac tagtataaca 60
 aa 62

5
 <210> 53
 <211> 62
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: HIV Consensus
 Sequence

10
 <400> 53
 acattgttaa cttgctggtc ccattgcac caggtcatgt tatcccagat atcctccaga 60
 ga 62

15
 <210> 54
 <211> 25
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: HIV Consensus
 Sequence

20
 <400> 54
 accggaattc cgatttcctt ggggtt 25

25
 <210> 55
 <211> 24
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: HIV Consensus
 Sequence

30
 <400> 55
 cataaagctt gtcccagaag ttcc 24

35
 <210> 56
 <211> 26
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: HIV Consensus
 Sequence

40
 <400> 56
 gccactgcag ccagactatt attgtc 26

45

<210> 57
 <211> 439
 <212> PRT
 <213> Artificial Sequence

5

<220>
 <223> Description of Artificial Sequence:HIV Consensus
 Sequence

10

<400> 57
 Met Arg Gly Ser Gly Ile Met Val Arg Pro Leu Asn Ser Ile Val Ala
 1 5 10 15

15

Val Ser Gln Asn Met Gly Ile Gly Lys Asn Gly Asp Leu Pro Trp Pro
 20 25 30

Pro Leu Arg Asn Glu Phe Lys Tyr Phe Gln Arg Met Thr Thr Thr Ser
 35 40 45

20

Ser Val Glu Gly Lys Gln Asn Leu Val Ile Met Gly Arg Lys Thr Trp
 50 55 60

Phe Ser Ile Pro Glu Lys Asn Arg Pro Leu Lys Asp Arg Ile Asn Ile
 65 70 75 80

25

Val Leu Ser Arg Glu Leu Lys Glu Pro Pro Arg Gly Ala His Phe Leu
 85 90 95

30

Ala Lys Ser Leu Asp Asp Ala Leu Arg Leu Ile Glu Gln Pro Glu Leu
 100 105 110

Ala Ser Lys Val Asp Met Val Trp Ile Val Gly Gly Ser Ser Val Tyr
 115 120 125

35

Gln Glu Ala Met Asn Gln Pro Gly His Leu Arg Leu Phe Val Thr Arg
 130 135 140

Ile Met Gln Glu Phe Glu Ser Asp Thr Phe Phe Pro Glu Ile Asp Leu
 145 150 155 160

40

Gly Lys Tyr Lys Leu Leu Pro Glu Tyr Pro Gly Val Leu Ser Glu Val
 165 170 175

45

Gln Glu Glu Lys Gly Ile Lys Tyr Lys Phe Glu Val Tyr Glu Lys Lys
 180 185 190

Gly Ser Arg Ser Ala Arg Leu Leu Leu Ser Gly Ile Val Gln Gln Gln
 195 200 205

50

Asn Asn Leu Leu Arg Ala Ile Glu Ala Gln Gln His Met Leu Gln Leu
 210 215 220

Thr Ala Trp Gly Ile Lys Gln Leu Arg Ala Arg Leu Gln Ala Leu Glu
 225 230 235 240

	Thr	Leu	Met	Gln	Asn	Gln	Gln	Arg	Leu	Asn	Ser	Trp	Gly	Cys	Lys	Gly
					245					250					255	
5	Arg	Ile	Ile	Cys	Tyr	Thr	Ser	Ala	Arg	Trp	His	Ala	Ser	Trp	Ser	Asn
				260					265					270		
	Lys	Ser	Leu	Glu	Asp	Ile	Trp	Asp	Asn	Met	Thr	Trp	Met	Gln	Trp	Asp
			275					280					285			
10	Gln	Gln	Val	Asn	Asn	Val	Ser	Ser	Ile	Ile	Tyr	Asp	Lys	Ile	Leu	Glu
			290				295					300				
	Ala	Gln	Asp	Gln	Gln	Glu	Glu	Asn	Val	Arg	Glu	Leu	Leu	Glu	Leu	Asp
15	305					310					315					320
	Lys	Trp	Ala	Ser	Leu	Trp	Asn	Trp	Phe	Asp	Ile	Thr	Asn	Trp	Leu	Trp
					325					330					335	
20	Tyr	Ile	Lys	Ile	Phe	Ile	Met	Ile	Val	Gly	Gly	Leu	Val	Gly	Leu	Arg
				340					345					350		
	Ile	Val	Phe	Ala	Val	Leu	Ser	Ile	Val	Asn	Arg	Val	Arg	Gln	Gly	Tyr
			355					360					365			
25	Ser	Pro	Leu	Ser	Leu	Gln	Thr	Arg	Pro	Pro	Val	Pro	Arg	Gly	Pro	Asp
		370					375					380				
	Arg	Pro	Glu	Gly	Ile	Glu	Glu	Glu	Gly	Gly	Glu	Arg	Asp	Arg	Asp	Thr
30	385					390					395					400
	Ser	Gly	Arg	Leu	Val	His	Gly	Phe	Leu	Ala	Ile	Ile	Trp	Val	Asp	Leu
					405					410					415	
35	Gly	Pro	Glu	Gln	Lys	Leu	Ile	Ser	Glu	Glu	Asp	Leu	Asn	Ser	Ala	Val
				420					425					430		
	Asp	His	His	His	His	His	His									
40				435												

<210> 58
 <211> 368
 <212> PRT
 <213> Artificial Sequence

5

<220>
 <223> Description of Artificial Sequence:HIV Consensus
 Sequence

10

<400> 58
 Met Arg Gly Ser Gly Ile Met Val Arg Pro Leu Asn Ser Ile Val Ala
 1 5 10 15

15

Val Ser Gln Asn Met Gly Ile Gly Lys Asn Gly Asp Leu Pro Trp Pro
 20 25 30

Pro Leu Arg Asn Glu Phe Lys Tyr Phe Gln Arg Met Thr Thr Thr Ser
 35 40 45

20

Ser Val Glu Gly Lys Gln Asn Leu Val Ile Met Gly Arg Lys Thr Trp
 50 55 60

Phe Ser Ile Pro Glu Lys Asn Arg Pro Leu Lys Asp Arg Ile Asn Ile
 65 70 75 80

25

Val Leu Ser Arg Glu Leu Lys Glu Pro Pro Arg Gly Ala His Phe Leu
 85 90 95

30

Ala Lys Ser Leu Asp Asp Ala Leu Arg Leu Ile Glu Gln Pro Glu Leu
 100 105 110

Ala Ser Lys Val Asp Met Val Trp Ile Val Gly Gly Ser Ser Val Tyr
 115 120 125

35

Gln Glu Ala Met Asn Gln Pro Gly His Leu Arg Leu Phe Val Thr Arg
 130 135 140

Ile Met Gln Glu Phe Glu Ser Asp Thr Phe Phe Pro Glu Ile Asp Leu
 145 150 155 160

40

Gly Lys Tyr Lys Leu Leu Pro Glu Tyr Pro Gly Val Leu Ser Glu Val
 165 170 175

45

Gln Glu Glu Lys Gly Ile Lys Tyr Lys Phe Glu Val Tyr Glu Lys Lys
 180 185 190

Gly Ser Arg Ser Ala Arg Leu Leu Leu Ser Gly Ile Val Gln Gln Gln
 195 200 205

50

Asn Asn Leu Leu Arg Ala Ile Glu Ala Gln Gln His Met Leu Gln Leu
 210 215 220

Thr Ala Trp Gly Ile Lys Gln Leu Arg Ala Arg Leu Gln Ala Leu Glu
 225 230 235 240

Thr Leu Met Gln Asn Gln Gln Arg Leu Asn Ser Trp Gly Cys Lys Gly
245 250 255

5 Arg Ile Ile Cys Tyr Thr Ser Ala Arg Trp His Ala Ser Trp Ser Asn
260 265 270

Lys Ser Leu Glu Asp Ile Trp Asp Asn Met Thr Trp Met Gln Trp Asp
275 280 285

10 Gln Gln Val Asn Asn Val Ser Ser Ile Ile Tyr Asp Lys Ile Leu Glu
290 295 300

15 Ala Gln Asp Gln Gln Glu Glu Asn Val Arg Glu Leu Leu Glu Leu Asp
305 310 315 320

Lys Trp Ala Ser Leu Trp Asn Trp Phe Asp Ile Thr Asn Trp Leu Trp
325 330 335

20 Tyr Ile Lys Ile Phe Ile Met Ile Val Gly Pro Glu Gln Lys Leu Ile
340 345 350

Ser Glu Glu Asp Leu Asn Ser Ala Val Asp His His His His His His
355 360 365

25

30 <210> 59
<211> 23
<212> PRT
<213> Artificial Sequence

35 <220>
<223> Description of Artificial Sequence:HIV Consensus
Sequence

40 <400> 59
Asn Gln Gln Arg Leu Asn Ser Trp Gly Cys Lys Gly Arg Ile Ile Cys
1 5 10 15

Tyr Thr Ser Ala Arg Trp His
20

45

50 <210> 60
<211> 23
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:HIV Consensus
Sequence

<400> 60
Xaa Gln Gln Arg Leu Asn Ser Trp Gly Cys Lys Gly Arg Ile Ile Cys
1 5 10 15

Tyr Thr Ser Ala Arg Trp His
20

<210> 61
<211> 23
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:HIV Consensus
Sequence

<400> 61
Glu Gln Gln Arg Leu Asn Ser Trp Gly Cys Lys Gly Arg Ile Ile Cys
1 5 10 15

Tyr Thr Ser Ala Arg Trp His
20

<210> 62
<211> 28
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:HIV Consensus
Sequence

<400> 62
Glu Thr Leu Met Gln Xaa Gln Gln Arg Leu Asn Ser Trp Gly Cys Lys
1 5 10 15

Gly Arg Ile Ile Cys Tyr Thr Ser Ala Arg Trp His
20 25

<210> 63
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:HIV Consensus
Sequence

<400> 63

Gly Arg Glu Thr Leu Met Gln Xaa Gln Gln Arg Leu Asn Ser Trp Gly
1 5 10 15

5 Cys Lys Gly Arg Ile Ile Cys Tyr Thr Ser Ala Arg Trp His
20 25 30

<210> 64

10 <211> 35

<212> PRT

<213> Artificial Sequence

<220>

15 <223> Description of Artificial Sequence:HIV Consensus
Sequence

<400> 64

20 Arg Ala Arg Leu Gln Ala Leu Glu Thr Leu Met Gln Xaa Gln Gln Arg
1 5 10 15

Leu Asn Ser Trp Gly Cys Lys Gly Arg Ile Ile Cys Tyr Thr Ser Ala
20 25 30

25 Arg Trp His
35

<210> 65

30 <211> 33

<212> PRT

<213> Artificial Sequence

<220>

35 <223> Description of Artificial Sequence:HIV Consensus
Sequence

<400> 65

40 Asp Gln Gln Val Asn Asn Val Ser Ser Ile Ile Tyr Asp Lys Ile Leu
1 5 10 15

Glu Ala Gln Asp Gln Gln Glu Glu Asn Val Arg Glu Leu Leu Glu Leu
20 25 30

45 Asp

<210> 66

50 <211> 220

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:HIV Consensus
Sequence

<400> 66

5 Ala Arg Leu Leu Leu Ser Gly Ile Val Gln Gln Gln Asn Asn Leu Leu
1 5 10 15

Arg Ala Ile Glu Ala Gln Gln His Met Leu Gln Leu Thr Ala Trp Gly
20 25 30

10 Ile Lys Gln Leu Arg Ala Arg Leu Gln Ala Leu Glu Thr Leu Met Gln
35 40 45

15 Asn Gln Gln Arg Leu Asn Ser Trp Gly Cys Lys Gly Arg Ile Ile Cys
50 55 60

Tyr Thr Ser Ala Arg Trp His Ala Ser Trp Ser Asn Lys Ser Leu Glu
65 70 75 80

20 Asp Ile Trp Asp Asn Met Thr Trp Met Gln Trp Asp Gln Gln Val Asn
85 90 95

25 Asn Val Ser Ser Ile Ile Tyr Asp Lys Ile Leu Glu Ala Gln Asp Gln
100 105 110

Gln Glu Glu Asn Val Arg Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser
115 120 125

30 Leu Trp Asn Trp Phe Asp Ile Thr Asn Trp Leu Trp Tyr Ile Lys Ile
130 135 140

Phe Ile Met Ile Val Gly Gly Leu Val Gly Leu Arg Ile Val Phe Ala
145 150 155 160

35 Val Leu Ser Ile Val Asn Arg Val Arg Gln Gly Tyr Ser Pro Leu Ser
165 170 175

40 Leu Gln Thr Arg Pro Pro Val Pro Arg Gly Pro Asp Arg Pro Glu Gly
180 185 190

Ile Glu Glu Glu Gly Gly Glu Arg Asp Arg Asp Thr Ser Gly Arg Leu
195 200 205

45 Val His Gly Phe Leu Ala Ile Ile Trp Val Asp Leu
210 215 220

<210> 67

<211> 149

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:HIV Consensus

Sequence

<400> 67

Ala Arg Leu Leu Leu Ser Gly Ile Val Gln Gln Gln Asn Asn Leu Leu
1 5 10 15

Arg Ala Ile Glu Ala Gln Gln His Met Leu Gln Leu Thr Ala Trp Gly
20 25 30

Ile Lys Gln Leu Arg Ala Arg Leu Gln Ala Leu Glu Thr Leu Met Gln
35 40 45

Asn Gln Gln Arg Leu Asn Ser Trp Gly Cys Lys Gly Arg Ile Ile Cys
50 55 60

Tyr Thr Ser Ala Arg Trp His Ala Ser Trp Ser Asn Lys Ser Leu Glu
65 70 75 80

Asp Ile Trp Asp Asn Met Thr Trp Met Gln Trp Asp Gln Gln Val Asn
85 90 95

Asn Val Ser Ser Ile Ile Tyr Asp Lys Ile Leu Glu Ala Gln Asp Gln
100 105 110

Gln Glu Glu Asn Val Arg Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser
115 120 125

Leu Trp Asn Trp Phe Asp Ile Thr Asn Trp Leu Trp Tyr Ile Lys Ile
130 135 140

Phe Ile Met Ile Val
145

<210> 68

<211> 23

<212> PRT

<213> Human immunodeficiency virus type 1

<400> 68

Asn Gln Gln Leu Leu Ser Leu Trp Gly Cys Lys Gly Lys Leu Val Cys
1 5 10 15

Tyr Thr Ser Val Lys Trp Asn
20

<210> 69

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HIV Consensus

Sequence

<400> 69

Gly Arg Glu Thr Leu Met Gln Asp Gln Gln Arg Leu Asn Ser Trp Gly
1 5 10 15

Cys Lys Gly Arg Ile Ile Cys Tyr Thr Ser Ala Arg Trp His
20 25 30

<210> 70

<211> 160

<212> PRT

<213> Human immunodeficiency virus type 1

<400> 70

Ala Ala Ile Gly Ala Leu Phe Leu Gly Phe Leu Gly Ala Ala Gly Ser
1 5 10 15

Thr Met Gly Ala Ala Ser Val Thr Leu Thr Val Gln Ala Arg Leu Leu
20 25 30

Leu Ser Gly Ile Val Gln Gln Gln Asn Asn Leu Leu Arg Ala Ile Glu
35 40 45

Ala Gln Gln His Met Leu Gln Leu Thr Val Trp Gly Ile Lys Gln Leu
50 55 60

Gln Ala Arg Val Leu Ala Val Glu Arg Tyr Leu Lys Asp Gln Gln Leu
65 70 75 80

Leu Gly Phe Trp Gly Cys Ser Gly Lys Leu Ile Cys Thr Thr Thr Val
85 90 95

Pro Trp Asn Ala Ser Trp Ser Asn Lys Ser Leu Asp Asp Ile Trp Asn
100 105 110

Asn Met Thr Trp Met Gln Trp Glu Arg Glu Ile Asp Asn Tyr Thr Ser
115 120 125

Leu Ile Tyr Ser Leu Leu Glu Lys Ser Gln Thr Gln Gln Glu Lys Asn
130 135 140

Glu Gln Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu Trp Asn Trp
145 150 155 160

We claim:

1. A peptide comprising an amino acid sequence selected from the group consisting of:
(SEQ ID NO:59) NQQRLNSWGCKGRIICYTSARWH,
(SEQ ID NO:61) EQQRLNSWGCKGRIICYTSARWH,
(SEQ ID NO:69) GRETLMQDQQRLNSWGCKGRIICYTSARWH
(SEQ ID NO:60) XQQRLNSWGCKGRIICYTSARWH,
(SEQ ID NO:62) ETLMQXQQRLNSWGCKGRIICYTSARWH,
(SEQ ID NO:64) RARLQALETLMQNQQRLNSWGCKGRIICYTSARWH,
(SEQ ID NO:65) DQQVNNVSSIIYDKILEAQDQQEENVRELLELD and
functional derivatives thereof.
2. The peptide of claim 1 wherein said peptide is antigenic.
3. The peptide of claim 1 wherein said peptide binds anti-HIV group O
antibodies.
4. An antibody raised against the peptide of claim 1.
5. The peptide of claim 1 wherein said peptide is made by recombinant or
synthetic chemistry methods.
6. A nucleic acid sequence that encodes the peptide of claim 1.
7. A vector for expression containing the nucleic acid sequence of claim 6.
8. A host cell containing the expression vector of claim 8.
9. A process for expression of a peptide in a recombinant host cell,
comprising: (a) transferring the expression vector of claim 7 into suitable

host cells, and (b) culturing the host cells of step (a) under a condition which allows expression of the peptide from the expression vector.

10. A test kit comprising one or more peptides selected from the group consisting of:

(SEQ ID NO:59) NQQRLNSWGCKGRIICYTSARWH,
(SEQ ID NO:61) EQQRLNSWGCKGRIICYTSARWH,
(SEQ ID NO:69) GRETLMQDQQRLNSWGCKGRIICYTSARWH
(SEQ ID NO:60) XQQRLNSWGCKGRIICYTSARWH,
(SEQ ID NO:62) ETLMQXQQRLNSWGCKGRIICYTSARWH,
(SEQ ID NO:64) RARLQALETLMQNQQRLNSWGCKGRIICYTSARWH,
(SEQ ID NO:65) DQQVNNVSSIIYDKILEAQDQQEENVRELLELD and,
functional derivatives thereof, antibodies that bind to said peptides, and
antibodies that bind to said functional derivatives thereof.

11. An in vitro diagnostic assay method comprising contacting a sample with one or more peptides selected from the group consisting of:

(SEQ ID NO:59) NQQRLNSWGCKGRIICYTSARWH,
(SEQ ID NO:61) EQQRLNSWGCKGRIICYTSARWH,
(SEQ ID NO:69) GRETLMQDQQRLNSWGCKGRIICYTSARWH
(SEQ ID NO:60) XQQRLNSWGCKGRIICYTSARWH,
(SEQ ID NO:62) ETLMQXQQRLNSWGCKGRIICYTSARWH,
(SEQ ID NO:64) RARLQALETLMQNQQRLNSWGCKGRIICYTSARWH,
(SEQ ID NO:65) DQQVNNVSSIIYDKILEAQDQQEENVRELLELD and,
and functional derivatives thereof and determining binding between said
peptide and an antibody.

12. An in vitro diagnostic assay method comprising contacting a sample with one or more antibodies raised against a peptide of claim 1 or a functional

derivative thereof and determining binding between said antibodies and an antigen.

13. A mosaic comprising a recombinant group M gp 41 protein wherein a group M immunodominant region has been replaced by one or more O-like immunodominant sequences.

14. The mosaic of claim 13 wherein the O-like immunodominant sequence is selected from the group consisting of:

(SEQ ID NO:59) NQQRLNSWGCKGRIICYTSARWH,
(SEQ ID NO:61) EQQRLNSWGCKGRIICYTSARWH,
(SEQ ID NO:69) GRETLMQDQQRLNSWGCKGRIICYTSARWH
(SEQ ID NO:60) XQQRLNSWGCKGRIICYTSARWH,
(SEQ ID NO:62) ETLMQXQQRLNSWGCKGRIICYTSARWH,
(SEQ ID NO:64) RARLQALETLMQNQQRLNSWGCKGRIICYTSARWH,
(SEQ ID NO:65) DQQVNNVSSIIYDKILEAQDQQEENVRELLELD and,
and functional derivatives thereof.

15. A mosaic comprising a recombinant group M gp 41 protein wherein a group M immunodominant region has been replaced by one or more O-like immunodominant sequences wherein said mosaic is selected from the group consisting of:

(SEQ ID NO:66) ARLLLSGIVQQQNNLLRAIEAQQHMLQLTAWGIKQL
RARLQALETLMQNQQRLNSWGCKGRIICYTSARWHASWSNKSLEDIW
DNMTWMQWDQQVNNVSSIIYDKILEAQDQQEENVRELLELDKWASLW
NWFDTNWLWYIKIFIMIVGGLVGLRIVFAVLSIVNRVRQGYSPLSLQTRP
PVPRGPDRPEGIEEEGERDRDTSGRLVHGFLAIWVDL

and

(SEQ ID NO:67) ARLLLSGIVQQQNNLLRAIEAQQHMLQLTAWGIKQLRA
RLQALETLMQNQQRLNSWGCKGRIICYTSARWHASWSNKSLEDIWDNMT
WMQWDQQVNNVSSIIYDKILEAQDQQEENVRELLELDKWASLWNWFDITN
WLWYIKIFIMIV.

ABSTRACT OF THE INVENTION

5 This invention relates to peptides and their preparation. The peptides each
have a sequence that corresponds to the immunodominant region of the HIV-1
group O gp41 envelope protein. The sequence is characterized in that it does
not correspond to any known naturally occurring group O sequence or variant.
Furthermore, the peptide binds anti-HIV-1 group O antibodies. There are
10 several uses for the peptides, including the detection of antibodies produced in
response to HIV-1 group O infection. The peptides may also be incorporated
in mosaics and expressed recombinantly.




Figure 1. Alignment of HIV-1 group O immunodominant region amino acid sequences

SEQ ID NO: 70

514
AAIGALLFLGFLGAGSTMGASVTLTVQARLLLSGLVQOQNNLLRALEAQOHMLQLFTWGLKQLQARVLAVERYLKDQQL
LGFWGCSGKLICTTVPMNASWSNKSLLDDIMNNMTWMQWEREIDNYTSLIYSLLEKSQTQOEKNEQELFELDKNASLWNW
immunodominant region
↓
descending helix
673

Figure 3. Ectodomain of gp41 (MN isolate)

[illegible]




Figure 4. Alignment of MN (type B) and group O gp41 sequences in the region of the descending helix




Figure 5a.




Figure 5b.




Figure 5c.

bioRxiv preprint doi: <https://doi.org/10.1101/2017.08.01.110111>; this version posted August 1, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

Primers used in the experiment:

SEQ ID NO:46	FA:	5'-ATTTGAAGCCCCAGGATCAACAAGAGAGAACGTTCTGAGTTGCTGGAGCTAGATAAATGG
SEQ ID NO:47	FB:	5'-AGCAAGTTAACCAATGTTTCTTCTATTAATTATGATAAGATTTTGAAGCCCAAGATCA
SEQ ID NO:48	RA:	5'-CAAGAATTCAAGCGCTGTGGTTTTCATCAGAGTCTCCAGAGCCTGTAGGCGAGCTCGAGCTG
SEQ ID NO:49	RB:	5'-GGGCACCTAGTATTAACAATAATATACGACCCTTACAACCCCAAGAAITCAGACGCTGT
SEQ ID NO:50	RC:	5'-CCAGATATCCCTCCAGAGACTTATTAGACCAGAAGCATGCCAACGGGCACTAGTATAACAAA
SEQ ID NO:51	RD:	5'-ACATTGTTACTTGCTGTGTCCTCCATTGCATCCAGGTCAATGTTATCCAGATATCCTCCAGAGA
SEQ ID NO:52	U19:	5'-GTTTCCAGTCACGACGT
SEQ ID NO:53	R20:	5'-CAGCTATGACCATGATTACG
SEQ ID NO:54	R33-3:5'	-ACCGGAATTCGATTTCCTGGGTT
SEQ ID NO:55	F33-2:5'	-CATTAAGCTTGTCCCAAGATTCC
SEQ ID NO:56	F33-6:5'	-GCCACTGCAGCCAGACTATTATTGTC

Figure 5d. Nucleotide sequences of the primers used in Figures a - c.

SEQ ID NO:57

DHFR

MRGSGIMVRPLNSIVAVSQNMGI GKN GDL PMPPLRNEFKYFQRM TTSVEGKQNLVIMGRKTWESI PEKNRPLKDRINI

VLSRELKEPPRGAFHFLAKSLD DALRLIEQPELASKVDMWVI VGGSSVQEA MNQPGHLRLFVTRIMQEFESDTEFFPEIDL

GKYYKLPEYPGVLESEVQEEKGI KYKPEVYEKKGSRARLLSGIVQOQNNLLRAIEAQQHMLQLTAWGI KQLRARLQALE

TLMNQQR LNSWGCKGRIICYTSARWHA SWSNKSLEDIWDNMTWMQWDQVNNVSSIYDKILLEAQDQQEEENVRELLLELD

KWASLWNWFDTNNWLWYIKIFIMI VGLVGLRIVFAVLSTVNRVRQGYSPLSLQTRPPVPRGPD RPEGIEEGGERDRT

SGRLVHGFLAI IWDLGPEOKLISEEDLNSAVDHHHHH

myc (His)₆

Figure 6a. Amino acid sequence of DHFR-hENV-MH

dhfr henv mh
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

DHLER

MRGSGIMVRPLNSI VAVSÖNMGI GKNGLPWPPLRNEFKY FÖRM T T TSSVEGKÖNL VIMGRKIWFS IPEKNRPLKDRINI

VL\$RELKEPPRG\$HFLAKSLDDALRLIEQPELASKVDMWIVGSSVYO\$EAMNO\$PCHLRLFLVRIMOE\$FESDTEFPEIDL

GKYKLLPEYPVGLSEVQEEKIKYKFEVYEKKGSRARLLSGIVQÖÖNNLLRAIEAQÖHMLÖLTAWGIKÖLRARLÖALE

TLMNQORLNSWGCKGRIICYTSARWHAWSNKSLEDIWDNMTWMQWDQOVNVSSI IYDKILLEAQDQEEENVRELELEL

KWASLWNWFDTNWLMIKIFIMVGP EÖKLISEEDLSAVDHHHHHH

myc (His)₆

Figure 6b. Sequence of DHFR-hES-MH

DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled PEPTIDES FOR THE DETECTION OF HIV-1 GROUP O, the specification of which

(check one) ☒ is attached hereto.

☐ was filed on _____ as

Application Serial No. _____

and was amended on _____.
(if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 (a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s):

Country	Application Number	Date of Filing	Priority Claimed Under 35 U.S.C. 119	
			<input type="checkbox"/> YES	<input type="checkbox"/> NO
			<input type="checkbox"/> YES	<input type="checkbox"/> NO
			<input type="checkbox"/> YES	<input type="checkbox"/> NO

I hereby claim the benefit under Title 35, United States Code, **§119(e)** of any United States provisional application(s) listed below:

60/110,292
(Application Number)

November 30, 1999
(Filing Date)

60/119,138
(Application Number)

February 8, 1999
(Filing Date)

I hereby claim the benefit under Title 35, United States Code, **§120** of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, **§112**, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, **§1.56(a)** which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

<u>Application Serial No.</u>	<u>Filing Date</u>	<u>Status</u>
-------------------------------	--------------------	---------------

<u>Application Serial No.</u>	<u>Filing Date</u>	<u>Status</u>
-------------------------------	--------------------	---------------


I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith as well as to file equivalent patent applications in countries foreign to the United States including the filing of international patent applications in accordance with the Patent Cooperation Treaty: Audley A. Ciamporcerro, Jr. (Reg. #26,051), Steven P. Berman (Reg. #24,772), Andrea L. Colby (Reg. #30,194), Michael Stark (Reg. #32,495), and Stacey B. Antar (Reg. #39,595) One Johnson & Johnson Plaza, New Brunswick, NJ 08933.

Address all telephone calls to Stacey B. Antar at telephone no.
(732) 524-2824.

Address all correspondence to Audley A. Ciamporcerro, Jr., One
Johnson & Johnson Plaza, New Brunswick, NJ 08933-7003.

I hereby declare that all statements made herein of my own
knowledge are true and that all statements made on information
and belief are believed to be true; and further that these
statements were made with the knowledge that willful false
statements and the like so made are punishable by fine or
imprisonment, or both, under Section 1001 of Title 18 of the
United States Code and that such willful false statements may
jeopardize the validity of the application or any patent issued
thereon.

Inventor's Signature:
Full Name of Sole
or First Inventor


Robert De Leys

Date: 1 November 1999

Citizenship: USA
Residence: 273 Kingbird Court, Three Bridges, NJ 08887-2128
Post Office Address: Same as above

Inventor's Signature:
Full Name of Second Joint
Inventor, If Any


Jian Zheng

Date: Nov. 1st, 1999

Citizenship: China
Residence: 7 Renzi Road, Raritan, NJ 08869
Post Office Address: Same as above